Previous 10 | Next 10 |
HOLLISTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) conference from November 12-15, 2023, in Washington, D.C. Complementing an already extensive ...
HOLLISTON, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2023 before the market opens on November 7, 2023, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. ...
Includes dedicated version for integration with Ponemah data management software from Data Sciences International (DSI) Expands reach of unique, non-invasive wearable monitoring for pre-clinical research across North American and European markets HOLLISTON, Mass. and LYON, France,...
2023-09-07 07:54:42 ET Summary Harvard Bioscience's Q2 earnings showed a slight miss on EPS and revenue, causing a decline in the stock price. The company is committed to improving its product portfolio and has observed increased traction from new products launched last year. ...
NEW YORK, NY / ACCESSWIRE / August 15, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 16-17, 2023. The presentation schedule is subje...
2023-08-08 13:55:25 ET Harvard Bioscience, Inc. (HBIO) Q2 2023 Earnings Conference Call August 8, 2023 08:00 ET Company Participants Dave Sirois - Director, Corporate Accounting & SEC Reporting James Green - Chairman, President & Chief Executive Officer J...
2023-08-08 07:47:53 ET Harvard Bioscience press release ( NASDAQ: HBIO ): Q2 Non-GAAP EPS of $0.04 misses by $0.02 . Revenue of $28.2M (-3.4% Y/Y) misses by $1.3M . For further details see: Harvard Bioscience Non-GAAP EPS of $0.04 misses by $0.02, revenue...
Q2 Revenues of $28.8 million Q2 GAAP operating income $0.8 million, adjusted operating income $3.6 million Strong H1 operating cash flow drove net debt reduction of $5.4 million HOLLISTON, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO)...
HOLLISTON, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present to investors at the Sidoti August Virtual Investor Conference on August 16, 2023. Joining him will be Jennifer Cote, the com...
HOLLISTON, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2023 before the market opens on August 8, 2023, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Pa...
News, Short Squeeze, Breakout and More Instantly...
Harvard Bioscience Inc. Company Name:
HBIO Stock Symbol:
NASDAQ Market:
Harvard Bioscience Inc. Website:
HOLLISTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced that Jim Green, Chairman and Chief Exe...
HOLLISTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Benchmark Healthcare House Call Virtual Conference on May 22 ...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...